|
BioScreening - organic compounds for screening
News: Cancer ResearchAnti-cancer compound wins scientist Biota Award - Walter and Eliza Hall Institute scientist Dr Guillaume Lessene has won this year’s Biota Award for Medicinal Chemistry, awarded by the Royal Australian Chemical Institute.
Dr Lessene, who runs a laboratory in the institute’s Structural Biology Division, won the award for his role in the discovery of several compounds that interact with a protein that has [...]
AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline - The last decade has seen a major expansion in the cancer drug pipeline and studies are continually underway to advance the arsenal of drugs and create more effective treatments and targeted therapies for patients.
To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on [...]
Tapeworm Drug May Hold Promise For Colon Cancer, Future Research - The findings about this compound, published in the Nov. 3 issue of Biochemistry journal, might prove valuable to patients and clinicians, who may benefit if there is a demonstrated boost to chemotherapy. Researchers also can use the compound to manipulate the receptor to learn more about a common cell replenishing pathway, called the Wnt pathway, [...]
Glycotope receives regulatory approval for GlycoExpressTM Technology and initiates first clinical trial with lead antibody GT-MAB 2.5-GEX TM - Berlin, Germany, November 25, 2009 / b3c newswire / - Glycotope GmbH, a leading German Biotech company, has received regulatory approval by Germany and Italian regulatory authorities for a Phase I study of Glycotope´s lead antibody GT-MAB 2.5-GEXTM for the treatment of various solid cancers. The approvals further underline the [...]
Scientists hope mouse research leads to new anti-cancer therapies - Can an experiment with rodents lead to the end of breast cancer as we know it?
Recent collaborative work between Cambridge, Mass., research institutes has discovered a method of screening for chemicals that selectively kill breast cancer stem cells in culture and in mice, a breakthrough that may directly or indirectly lead to new anti-cancer therapies.
“One [...]
PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test - OTTAWA, ONTARIO, Oct 27, 2009 (MARKETWIRE via COMTEX) —-PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF) (”PharmaGap” or “the Company”) is pleased to announce highly positive results from the United States National Cancer Institute (”NCI”) 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm [...]
PharmaGap Advises That NCI Test Results Are Completed and Expected to Be Provided to the Company Shortly - OTTAWA, ONTARIO — 10/20/09 — PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF) (”PharmaGap” or “the Company”) advises that the results of dose-range testing of the Company’s cancer drug GAP-107B8 at the United States National Cancer Institute (”NCI”) can be expected “shortly”. NCI staff has indicated to the Company that testing has been completed and the results [...]
Novel two-step chemical process makes cancer cells glow quickly, safely - WASHINGTON - Researchers at Massachusetts General Hospital have developed a two-step process that uses a chemical reaction to make live cancer cells light up quickly and safely.
This attains significance because scientists generally label cells with coloured or glowing chemicals to observe how basic cellular activities differ between healthy and cancerous cells, but existing techniques are [...]
New Method Takes Aim At Aggressive Cancer Cells - A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.
These cells, known as cancer stem cells, are thought to enable cancers to spread — and to reemerge after seemingly successful treatment. Although further [...]
Researchers develop screening test for cells that activate immune system - UT Southwestern Medical Center researchers are the first to design a large-scale, cell-based screening method that identifies which compounds activate immune-return cells that hold compact for prospective cancer-fighting vaccines.
The new screening technique can scan thousands and even millions of compounds to identify those that activate dendritic cells, which are on constant recon patrol throughout the [...]
Southern Research to Play Key Role in the Federal Government’s Search for New Cancer Therapies - National Cancer Institute Chemical Biology Consortium to coordinate academic, private and government cancer drug discovery efforts
BIRMINGHAM, Ala., Aug. 20 /PRNewswire-USNewswire/ — Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute’s (NCI) Chemical Biology Consortium (CBC)–a program meant to coordinate and accelerate the [...]
Vanderbilt Joins National Consortium to Develop New Cancer Therapies - Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.
As one of four Chemical Diversity Centers, Vanderbilt’s role in the consortium will be to synthesize and optimize new [...]
Killing Cancer Stem Cells - Recent evidence suggests that certain cancers may persist or recur after treatment because a small population of cells, called cancer stem cells, remains behind to seed new tumors. Though scientists are not yet certain about the role cancer stem cells play in disease, evidence is accumulating that these cells are particularly resistant to chemotherapy and [...]
Boston, MA - Drug Compound That Kills Cancer Stem Cells Identified - Boston, MA - A drug that can selectively target and kill the stem cells that drive the growth of tumors has been identified for the first time by scientists who searched more than 16,000 compounds to find it.
Researchers at Massachusetts Institute of Technology and the Broad Institute looked for compounds that could destroy the stem [...]
National Cancer Institute names Emory to nationwide NCI chemical biology consortium - CBC will support rapid development of innovative, targeted cancer therapies
Emory University’s Chemical Biology Discovery Center has been selected by SAIC-Frederick, Inc. (SAIC-F) to be part of an 11-member national consortium aimed at accelerating the discovery and development of new and innovative, targeted cancer therapies. SAIC-F is the prime contractor to the National Cancer Institute at [...]
Forma Therapeutics, Novartis team on cancer drugs - Forma Therapeutics Inc. said that it has entered into a collaboration agreement with Novartis AG to use Forma’s cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets to help develop cancer drugs.
No financial terms of the deal were disclosed. The funding arm of pharmaceutical giant Novartis, the Novartis Option Fund, was one of [...]
SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center - Menlo Park, Calif.—July 22 , 2009—SRI International, an independent nonprofit research and development organization, announced today that SRI’s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed “Chemical Biology Consortium” (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel [...]
Horizon Discovery signs screening agreement with SuperGen Inc. - Horizon Discovery today announced it has signed a commercial agreement with US Pharmaceutical company SuperGen, Inc., relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize [...]
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex - Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis [...]
Molecular Fingerprints Point The Way To Earlier Cancer Diagnosis And More Targeted Treatment - ScienceDaily (Mar. 27, 2009) — Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.
You’ve likely heard about metabolites; your physician probably screens for some known ones such as triglycerides or cholesterol at your annual physical. Scientists suspect we have about 3,000 [...]
Sponsored Links
|
|
